Envveno Medical Corporation · NASDAQ:NVNO
Envveno Medical — Hancock Jaffe Laboratories — 10th Indonesian Vascular Conference (October 2019)
14 slides from Envveno Medical's conference presentation, Oct 25, 2019
Slide 1: Hancock Jaffe Laboratories VenoValve First-in-Man Study Preliminary Data
HANCOCK JAFFE LABORATORIES VenoValveo Bogota, Colombia First-in-Man Study Preliminary Data October 2019
Slide 2: Prosthetic Valve for Post Thrombotic Syndrome
PROSTHETIC VALVE FOR POST THROMBOTIC SYNDROME JORGE H. ULLOA, MD., FACS October 25, 2019 = THE 10" INDONESIAN VASCULAR CONFERENCE oor > a x ad. \ SY q ; 4 \ & f i 2 \ = a
Slide 3: HJLI Legal Disclaimers
HJLI LEGAL DISCLAIMERS This presentation contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward looking statements are not statements of historical facts, but rather
Slide 4: Study End Points
STUDY END POINTS >Safety - infection; PE; native vein injury; allergic reaction >Reflux - measured by doppler with ultrasound >Venous Clinical Severity Score (VCSS) - 10 hallmarks of venous disease rated 0 to 3 in severity and administered by physician >Visual Analogue Scale(VAS) Score - intensity a
Slide 5: Safety
SAFETY >Nine Patients >1 Seroma >Intolerance from Coumadin therapy >2 Minor wound infections (erythema) treated with antibiotics
Slide 6: Month Data - Patients Summary
FIRST-IN-MAN - 6 MONTH DATA - PATIENTS 1 TO 5 - SUMMARY REFLUX vcss VAS (% Decrease) (% Decrease) (% Decrease) 80% 63% 75% BB BD AVERAGE 61% 59% 54%
Slide 7: Reflux by Patient
FIRST-IN-MAN - PATIENTS 1 TO 5 - REFLUX 3 3 3 80% Reduction 30% Reduction 100% Reduction 2 2 2 1 1 ili” a = ~~ ta09 0 aa wa = 0 Pre-Op14 30 60 90 180 Pre-Op 30 60 180 Pre-Op14 30 60 90 180 Patient #1 Patient Patient #3 3 3 65% Reduction 30% Reduction 2 2 1 1 = i Normal + - -| Normal ) 0) Pre-Op14 30
Slide 8: Reflux by Patient
FIRST-IN-MAN - PATIENTS 6 TO 8 - REFLUX 3 3 60% Reduction % Reduction 2 Haw __ a = =a, Pre-Op 14 peoe 14 30 60 Patient ~ Patient #7 35 ore -Op % Reduction Ug Ld i- 14 Patient e © 2019 Hancock Jaffe Laboratories, Inc.
Slide 9: VCSS Scores
FIRST-IN-MAN - PATIENTS 1 TO 5 - VCSS SCORES 20 20 20 63% Reduction 15 60% Reduction , 07% Reduction 10 wee on Pre -Op 30 60 Pre-Op 30 60 90 180 oon 30 60 90 Patient “- Patient #2 Patient #3 20 20 38% Reduction 15 15 10 10 5 5 Aiiit. ; ii Pre-Op 30 60 90 180 Pre-Op 30 60 90 180 Patient #4 Patient #5
Slide 10: VCSS Scores
FIRST-IN-MAN - PATIENTS 6 TO 8 - VCSS SCORES 20 20 20 % Reduction Reduction 17% Reduction 15 15 15 10 10 10 5 = 5 ) i ) eae 30 60 Pre-Op 30 60 Pre-Op 30 60 Patient #6 Patient #7 Patient #8 © 2019 Hancock Jaffe Laboratories, Inc.
Slide 11: VAS Scores
FIRST-IN-MAN - PATIENTS 1 TO 5 - VAS SCORES "75% Reduction 7 % Reduction ‘ 50% Reduction 6 6 6 4 4 4 0 a 10) 0 Pre-Op30 60 90 180 Pre-Op30 60 90 180 Pre-Op30 60 90 180 Patient #1 Patient #2 Patient #3 1 1 50% Reduction 38% Reduction 0) 0 8 8 6 6 4 4 2 2 0 0 Pre-Op30 60 90 180 Pre-Op30 60 90 180 Pati
Slide 12: VAS Scores
FIRST-IN-MAN - PATIENTS 6 TO 8 - VAS SCORES 10 10 10 75% Reduction ’ Reduction 60 Pre-Op 30 60 Pre-Op 38% Reduction oN KF DD 8 6 4 2 0 30 60 Patient #6 Patient #7 Patient #8 © 2019 Hancock Jaffe Laboratories, Inc.
Slide 13: VenoValve - C6 CVI Patient - Healing Venous Ulcer
VENOVALVE - C6 CVI PATIENT - HEALING VENOUS ULCER 30 Days © 2019 Hancock Jaffe Laboratories, Inc.
Slide 14: Hancock Jaffe Laboratories Inc
HANCOCK JAFFE LABORATORIES INC Nasdaq: HJLI
Hancock Jaffe Laboratories — 10th Indonesian Vascular Conference (October 2019) on 6ix